Prognostic significance of matrix metalloproteinase-9 (MMP-9) in stage II colorectal carcinoma

被引：34

作者：

Buhmeida A. ^{[1
,5
]}

Bendardaf R. ^{[1
]}

Hilska M. ^{[2
]}

Collan Y. ^{[3
]}

Laato M. ^{[2
]}

Syrjänen S. ^{[4
]}

Syrjänen K. ^{[1
]}

Pyrhönen S. ^{[1
]}

机构：

[1] Department of Oncology and Radiotherapy, Turku University Hospital, University of Turku, Turku

[2] Department of Surgery, Turku University Hospital, University of Turku, Turku

[3] Department of Pathology, Turku University Hospital, University of Turku, Turku

[4] Department of Oral Pathology, Turku University Hospital, University of Turku, Turku

[5] Department of Oncology and Radiotherapy, Turku University Hospital, Turku 20521

来源：

Journal of Gastrointestinal Cancer | 2009年 / 40卷 / 3-4期

关键词：

Adjuvant therapy; MMP-9; expression; Prognosis; Stage II CRC; Survival;

D O I：

10.1007/s12029-009-9091-x

中图分类号：

学科分类号：

摘要：

Background: Approximately 30% of all colorectal cancer patients are diagnosed with stage II disease. Adjuvant therapy is not widely recommended. However, it is well-established that a subgroup of patients with stage II is at high risk for recurrence within their life time and should be considered for adjuvant chemotherapy. The present work was designed to assess the value of matrix metalloproteinase-9 (MMP-9) as a predictor of disease outcome in a series of 202 stage II colorectal cancer (CRC) patients with long-term follow-up. Methods: The present study comprises a series of 202 patients who underwent bowel resection for stage II CRC at Turku University Hospital. Archival paraffin-embedded CRC tissue samples were used to prepare tissue microarray blocks for immunohistochemical staining with MMP-9 antibody. Results: Forty-eight percent of all CRC samples were positive for MMP-9. There was no significant correlation between MMP-9 expression and age, depth of invasion, and lymph node status. However, MMP-9 expression was significantly related to histological grade (p=0.03) and location of the tumor (p=0.01), therefore, being lower in high-grade tumors and most intense in carcinomas of the descending colon and rectum. Tumors with high MMP-9 expression showed a higher recurrence rate than tumors with low expression (p=0.02). MMP-9 negative tumors had a more favorable disease-free survival (DFS) than those expressing MMP-9 (p=0.03). The same was true with disease-specific survival (DSS; p=0.02) as well, high expression of MMP-9 being associated with shorter survival rates. In multivariate (Cox) survival analysis, MMP-9 expression proved to be an independent predictor of DFS, but not DSS, which was predicted by age and sex only. Conclusion: Quantification of MMP-9 expression seems to provide valuable prognostic information in stage II CRC, particularly, in selecting the patients at high risk for recurrent disease who might benefit from adjuvant therapy. © 2009 Humana Press Inc.

引用

页码：91 / 97

页数：6

共 28 条

[1]

Graziano F., Cascinu S., Prognostic molecular markers for planning adjuvant chemotherapy trials in Duke's B colorectal cancer patients: How much evidence is enough?, Annals of Oncology, 14, 7, pp. 1026-1038, (2003)

[2]

Curran S., Dundas S.R., Buxton J., Leeman M.F., Ramsay R., Murray G.I., Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers, Clinical Cancer Research, 10, 24, pp. 8229-8234, (2004)

[3]

Herszenyi L., Farinati F., Cardin R., Istvan G., Molnar L.D., Hritz I., De Paoli M., Plebani M., Tulassay Z., Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer, BMC Cancer, 8, (2008)

[4]

Fuchs C.S., Giovannucci E.L., Colditz G.A., Hunter D.J., Stampfer M.J., Rosner B., Speizer F.E., Willett W.C., Dietary fiber and the risk of colorectal cancer and adenoma in women, New England Journal of Medicine, 340, 3, pp. 169-176, (1999)

[5]

Benson III A.B., Schrag D., Somerfield M.R., Cohen A.M., Figueredo A.T., Flynn P.J., Krzyzanowska M.K., Maroun J., McAllister P., Van Cutsem E., Brouwers M., Charette M., Haller D.G., American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer, Journal of Clinical Oncology, 22, 16, pp. 3408-3419, (2004)

[6]

Venook A., Status of Adjuvant Chemotherapy for Stage II Colon Cancer, 81, (2004)

[7]

Elander N., Soderkvist P., Fransen K., Matrix metalloproteinase (MMP)-1, -2, -3 and -9 promoter polymorphisms in colorectal cancer, Anticancer Res, 26, 1 B, pp. 791-779, (2006)

[8]

Gum R., Lengyel E., Juarez J., Ji Hshiung Chen, Sato H., Seiki M., Boyd D., Stimulation of 92-kDa gelatinase B promoter activity by ras is mitogen- activated protein kinase kinase 1-independent and requires multiple transcription factor binding sites including closely spaced PEA3/ets and AP- 1 sequences, Journal of Biological Chemistry, 271, 18, pp. 10672-10680, (1996)

[9]

Herszenyi L., Hritz I., Pregun I., Sipos F., Juhasz M., Molnar B., Tulassay Z., Alterations of glutathione S-transferase and matrix metalloproteinase-9 expressions are early events in esophageal carcinogenesis, World J Gastroenterol, 13, 5, pp. 676-682, (2007)

[10]

Xing L.L., Wang Z.N., Jiang L., Zhang Y., Xu Y.Y., Li J., Luo Y., Zhang X., Matrix metalloproteinase-9-1562C>T polymorphism may increase the risk of lymphatic metastasis of colorectal cancer, World J Gastroenterol, 13, 34, pp. 4626-4629, (2007)

← 1 2 3 →